Menu
NASDAQ: PTX.O0.00$0.000.00)
LinkedInTwitterRSS
  • About Pernix
    • Our Purpose and Values
    • Leadership
      • Board of Directors
      • Executive Leadership Team
    • Partnerships
    • Corporate & Business Development
    • Locations
  • Products
    • Branded Products
      • TREXIMET®
      • Zohydro® ER
      • SILENOR®
    • Generic Products
    • Report an Adverse Event
  • Responsibility
    • Alertline
    • Pernix Compliance Program and Annual Declaration
    • Pernix Code of Business Conduct and Ethics
    • Corporate Governance
      • Committee Composition
      • Documents & Charters
      • Contact the Board
  • Investors
    • Overview
    • Stock Information
    • Press Releases
    • Events & Presentations
    • Financials
    • IRS
      • Form 8937 – Reverse Stock Split
    • Investor Contacts
    • Investor FAQs
  • Careers
    • Learn About Pernix
    • Employment and Labor Law Practice
    • Benefits
    • Search Jobs
Investors
SEC Filings
Form 8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 10/22/2018
Document Outline
Entire Document (17.8 KB)
Subdocument 1 - 8-K - 8-K
Page 1 - October 17, 2018
Page 2 - N/A
Page 3 - N/A
Related Links
  • SEC Filings
  • Annual Reports
  • Quarterly Results
  • Proxy Material
  • Financial Fundamentals
IR Toolkit
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet

© 2019 Pernix Therapeutics. All Rights Reserved.
This information is intended only for residents of the United States.

  • Contact Pernix
  • Terms of Use
  • Privacy Policy
  • Sitemap
Follow Us
LinkedInTwitterRSS